Medium materiality5/10
Argus upgrades Biogen to Buy
Why it may matterVerify against the original reporting
The explicit upgrade is a positive directional signal, tempered by the moderate implied upside and single-firm source.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Argus upgraded BIIB to Buy and cited a $280 target versus a posted price of $252.41, implying about 11% upside.
- Argus upgraded BIIB to Buy.
- The $280 target is about 11% above the cited price.
Key facts
- 01
Target: $280
- 02
Posted price: $252.41
- 03
Analyst firm: Argus Research
- 04
Analyst: Jasper Hellweg
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.